Literature DB >> 11668098

Mortality in severe meningococcal disease.

K Thorburn1, P Baines, A Thomson, C A Hart.   

Abstract

AIM: To evaluate mortality of critically ill children admitted with meningococcal disease.
METHODS: Prospective study of all children admitted to a regional paediatric intensive care unit (PICU) between January 1995 and March 1998 with meningococcal disease. Outcome measures were actual overall mortality, predicted mortality (by PRISM), and standardised mortality ratio.
RESULTS: A total of 123 children were admitted with meningococcal disease. There was an overall PICU mortality of 11 children (8.9%). The total mortality predicted by PRISM was 24.9. The standardised mortality ratio (SMR) was 0.44. Results were compared with those from four previously published meningococcal PICU studies (USA, Australia, UK, Netherlands) in which PRISM scores were calculated. The overall PICU mortality and SMR were lower than those in the previously published studies.
CONCLUSION: Compared with older studies and calibrating for disease severity, this study found a decrease in the mortality of critically ill children with meningococcal disease.

Entities:  

Mesh:

Year:  2001        PMID: 11668098      PMCID: PMC1718982          DOI: 10.1136/adc.85.5.382

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  25 in total

1.  Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study.

Authors:  P A Wylie; D Stevens; W Drake; J Stuart; K Cartwright
Journal:  BMJ       Date:  1997-09-27

2.  Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.

Authors:  B Derkx; J Wittes; R McCloskey
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

3.  Pediatric risk of mortality (PRISM) score.

Authors:  M M Pollack; U E Ruttimann; P R Getson
Journal:  Crit Care Med       Date:  1988-11       Impact factor: 7.598

4.  Prognosis of meningococcal septicaemia.

Authors:  J F Sinclair; C H Skeoch; D Hallworth
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

5.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

6.  Factors in the prognosis of meningococcal infection. Review of 63 cases with emphasis on recognition and management of the severely ill patient.

Authors:  E R Stiehm; D S Damrosch
Journal:  J Pediatr       Date:  1966-03       Impact factor: 4.406

7.  Pediatric risk of mortality (PRISM) score in meningococcal disease.

Authors:  M J van Brakel; A J van Vught; R J Gemke
Journal:  Eur J Pediatr       Date:  2000-04       Impact factor: 3.183

8.  Life-threatening heart failure in meningococcal septic shock in children: non-invasive measurement of cardiac parameters is of important prognostic value.

Authors:  W Hagmolen of ten Have; A Wiegman; G J van den Hoek; W B Vreede; H H Derkx
Journal:  Eur J Pediatr       Date:  2000-04       Impact factor: 3.183

9.  Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group.

Authors:  M Levin; P A Quint; B Goldstein; P Barton; J S Bradley; S D Shemie; T Yeh; S S Kim; D P Cafaro; P J Scannon; B P Giroir
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

10.  Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response syndrome with purpura.

Authors:  M L McManus; K B Churchwell
Journal:  Crit Care Med       Date:  1993-05       Impact factor: 7.598

View more
  23 in total

Review 1.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  Self Mutilating Behaviour in Severe Meningococcal Infection; An Interesting Association.

Authors:  Anju Dinkar; Jitendra Singh; Virendra Atam; Krishna Kumar Sahani; Munna Lal Patel
Journal:  J Clin Diagn Res       Date:  2016-05-01

3.  The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics.

Authors:  R S Heyderman; Y Ben-Shlomo; C A Brennan; M Somerset
Journal:  Arch Dis Child       Date:  2004-11       Impact factor: 3.791

Review 4.  Meningococcal disease and its management in children.

Authors:  C Anthony Hart; Alistair P J Thomson
Journal:  BMJ       Date:  2006-09-30

Review 5.  Emergency management of meningococcal disease: eight years on.

Authors:  Andrew J Pollard; Simon Nadel; Nelly Ninis; Saul N Faust; Michael Levin
Journal:  Arch Dis Child       Date:  2007-04       Impact factor: 3.791

Review 6.  Peptide-displaying phage technology in glycobiology.

Authors:  Michiko N Fukuda
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

7.  Prognostic utility of the semi-quantitative procalcitonin test, neutrophil count and C-reactive protein in meningococcal infection in children.

Authors:  Juan Casado-Flores; Alfredo Blanco-Quirós; Montserrat Nieto; Julia Asensio; Cristina Fernández
Journal:  Eur J Pediatr       Date:  2005-10-26       Impact factor: 3.183

8.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

9.  Long-term mortality in patients diagnosed with meningococcal disease: a Danish nationwide cohort study.

Authors:  Casper Roed; Lars Haukali Omland; Frederik Neess Engsig; Peter Skinhoj; Niels Obel
Journal:  PLoS One       Date:  2010-03-12       Impact factor: 3.240

Review 10.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.